SELLAS Life Sciences Group (SLS) stock is back in focus after CEO Angelos Stergiou said the Regal Phase 3 trial is nearing its 80 event trigger, while Martin Shkreli’s public critique added pressure and uncertainty.

The recent commentary around the Regal trial has arrived against a backdrop of strong momentum in SELLAS Life Sciences Group’s stock, with a 30 day share price return of 36.05% and a 90 day share price return of 176.68%. The 1 year total shareholder return is very large, reflecting how sentiment has shifted over a longer period.

If the recent volatility in SELLAS has you thinking more broadly about high growth opportunities in healthcare, it could be a moment to scan other cancer and biotech focused innovators using our healthcare AI stocks screener, starting with 39 healthcare AI stocks.

The market has driven SELLAS Life Sciences Group sharply higher, yet the stock still trades well below published analyst targets. Is this only caution around Regal’s binary risk, or a sign the discount is deserved?

Preferred Price to Book Multiple of 22.6x: Is It Justified?

SELLAS Life Sciences Group now carries a rich valuation on a P/B basis, with the share price at $12.34 and the stock trading on a 22.6x price to book multiple.

The P/B ratio compares what investors are paying for each dollar of net assets on the balance sheet to the company’s stated book value. For a late stage biotech like SELLAS Life Sciences Group, which is unprofitable and focused on clinical development, a high P/B often reflects how the market is weighing future trial outcomes and potential commercialisation against current financials.

In this case, the company reports no meaningful revenue, a net loss of $29.457m and a negative return on equity of 27.42%. Yet the P/B multiple sits well above many profitable businesses, which suggests the market is placing a high value on the pipeline and expectations for the business rather than present earnings.

Compared with peers, the difference is stark. SLS’s 22.6x P/B is expensive versus the US Biotechs industry average of 2.5x and also above the 8.6x peer group average cited in the checks, which signals that investors are currently paying a substantial premium relative to sector norms for this stock.

Result: Price-to-book of 22.6x (OVERVALUED)

However, SELLAS Life Sciences Group still faces clear risks, including the binary outcome of its late stage trials and the ongoing losses reported on zero revenue.

Next Steps

With sentiment this divided around SELLAS Life Sciences Group, it may be useful to review the data independently, move efficiently, and decide where you stand using 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond SELLAS Life Sciences Group?

If SELLAS Life Sciences Group has sharpened your focus on risk, reward and timing, do not stop here. Broaden your watchlist with a few targeted stock ideas.

• Spot potential upside early by scanning 21 elite penny stocks with strong financials that pair smaller market caps with stronger financial footing.
• Zero in on quality by using the solid balance sheet and fundamentals stocks screener (48 results) to focus on companies backed by healthier balance sheets and fundamentals.
• Hunt for overlooked potential with the screener containing 20 high quality undiscovered gems that screens for financially sound companies still flying under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.